A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors

Trial Profile

A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Binimetinib (Primary) ; Buparlisib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Array BioPharma; Novartis
  • Most Recent Events

    • 17 Jul 2017 Planned End Date changed from 30 Jun 2017 to 31 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 24 Nov 2015 Planned End Date changed from 1 Dec 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top